SA
GENE

Scarborough Advisors’s Genetic Technologies Ltd. GENE Stock Holding History

Scarborough Advisors’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,128
Closed -$8.11K – 735
2023
Q3 		$8.11K Hold
2,128
– – ﹤0.01% 72
2023
Q2 		$8.84K Hold
2,128
– – ﹤0.01% 68
2023
Q1 		$12.3K Buy
+2,128
New +$12.5K ﹤0.01% 64

Other funds holding GENE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Scarborough Advisors's GENE Position: Q4 2023 in Review

Scarborough Advisors sold out of Genetic Technologies Ltd. (GENE) in Q4 2023, closing a stake of 2,128 shares — an estimated $8.11K sold.

Scarborough Advisors first reported a position in GENE in Q1 2023 and held it in 3 quarters. The position peaked at $12.3K in Q1 2023. 6 funds tracked by Wall St. Rank hold GENE as of Q4 2023.

  • Scarborough Advisors reported no remaining Genetic Technologies Ltd. position as of Q4 2023 after selling out during the quarter.
  • Scarborough Advisors sold 2,128 Genetic Technologies Ltd. shares in Q4 2023, an estimated $8.11K.
  • Scarborough Advisors first reported a position in Genetic Technologies Ltd. in Q1 2023 and held it in 3 quarters.
  • Scarborough Advisors's Genetic Technologies Ltd. position peaked at $12.3K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2023.

Based on Scarborough Advisors's 13F filing for Q4 2023, filed 22 Feb 2024.